On September 11, 2025, Ocugen, Inc. signed an exclusive agreement with Kwangdong Pharmaceutical to license its OCU400 gene therapy for retinitis pigmentosa in South Korea, receiving $1 million upfront and potential milestone payments totaling $6.5 million, along with a 25% royalty on sales.